Published in Cancer Weekly, October 5th, 2004
Important results from the dose-escalating study were as follows:
-TNFerade, administered in combination with radiation therapy, was well tolerated with no dose limiting toxicities;
-2 of the 13 patients received TNFerade for palliation (to lessen the severity of symptoms) and did not undergo surgery while 11 patients received TNFerade as preoperative therapy;
-11 of the 13 evaluable...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.